J
John T. Vetto
Researcher at Oregon Health & Science University
Publications - 156
Citations - 8362
John T. Vetto is an academic researcher from Oregon Health & Science University. The author has contributed to research in topics: Sentinel lymph node & Melanoma. The author has an hindex of 40, co-authored 138 publications receiving 7837 citations. Previous affiliations of John T. Vetto include Lahey Hospital & Medical Center & Providence Portland Medical Center.
Papers
More filters
Journal ArticleDOI
Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer
Steven A. Rosenberg,Michael T. Lotze,Linda M. Muul,Susan F. Leitman,Alfred E. Chang,S. E. Ettinghausen,Yvedt L. Matory,John M. Skibber,Eitan Shiloni,John T. Vetto,Claudia A. Seipp,Colleen Simpson,Cheryl M. Reichert +12 more
TL;DR: Preliminary results of the systemic administration of autologous lymphokine-activated killer (LAK) cells and the recombinant-derived lymphokin interleukin-2 to patients with advanced cancer are described, based on animal models in which this regimen mediated the regression of established pulmonary and hepatic metastases from a variety of murine tumors in several strains of mice.
Journal ArticleDOI
High-Dose Recombinant Interleukin 2 in the Treatment of Patients With Disseminated Cancer: Responses, Treatment-Related Morbidity, and Histologic Findings
Michael T. Lotze,Alfred E. Chang,Claudia A. Seipp,Colleen Simpson,John T. Vetto,Steven A. Rosenberg +5 more
TL;DR: It is demonstrated that the administration of IL-2 can mediate the regression of established cancer in some patients.
Journal ArticleDOI
Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity
Andrew D. Weinberg,Martin Muy Rivera,Rodney A. Prell,Arden M. Morris,Trygg Ramstad,John T. Vetto,Walter J. Urba,Gregory Alvord,Campbell Bunce,John G. Shields +9 more
TL;DR: The data suggest that engagement of the OX-40R in vivo augments tumor- specific priming by stimulating/expanding the natural repertoire of the host’s tumor-specific CD4+ T cells.
Journal ArticleDOI
Clinical effects and toxicity of interleukin-2 in patients with cancer
Michael T. Lotze,Yvedt L. Matory,Anthony A. Rayner,S. E. Ettinghausen,John T. Vetto,Claudia A. Seipp,Steven A. Rosenberg +6 more
TL;DR: Interleukin‐2 derived from both natural and recombinant sources has been studied in Phase I protocols designed to evaluate toxicity in patients with a variety of solid tumors and to ascertain improvement in clinical parameters and immunologic status.
Journal ArticleDOI
Perioperative blood transfusions are associated with decreased time to recurrence and decreased survival after resection of colorectal liver metastases
Keith R. Stephenson,Seth M. Steinberg,Kevin S. Hughes,John T. Vetto,Paul H. Sugarbaker,Alfred E. Chang +5 more
TL;DR: It is concluded that the amount of perioperative blood transfused is an independent prognostic factor that adversely effects disease-free and overall survival.